[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stenosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,41,77,108,149,178,203,231,261,292,315,337,364],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100499235","diagnostic-performance-of-the-resistance-index-ri-for-the-assessment-of-cerebral-vasoreactivity-in-transcranial-doppler-100499235",false,"NCT05780619","Diagnostic Performance of the Resistance Index (RI) for the Assessment of Cerebral Vasoreactivity in Transcranial Doppler","REVACEIR","Inclusion Criteria:\n\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n* Stenosis ≥ 70% in diameter reduction in NASCET equivalent or occlusion of atheromatous origin of the cervical internal carotid artery, asymptomatic or symptomatic.\n* Presence of a temporal window sufficient to record the homolateral and contralateral middle cerebral artery.\n* Patient of legal age with free and informed consent.\n* Patient who has signed the consent form.\n* Patient affiliated or beneficiary of a health insurance plan.\n\nExclusion Criteria:\n\n* The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study\n* The subject refuses to sign the consent\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Contraindication to Acetazolamide Diamox® injection.\n* Absence of temporal acoustic window (non visualization of the cerebral parenchyma, no recordable intracranial vessel).\n* Insufficient temporal window (visualizable brain parenchyma, no recordable MCA)\n* Internal or common carotid artery stenosis ≥70% or occlusion, contralateral to the primary lesion.\n* Stenosis ≥50% of the middle cerebral artery homolateral or contralateral to the cervical lesion.\n* Patient in exclusion period determined by another study.\n* Patient under court protection, guardianship, or conservatorship.\n* Patient refusing to sign the consent form.\n* Patient unable to express his or her will (dementia, disturbed consciousness, etc.)\n* Patient for whom it is impossible to give informed information for health reasons or because of a language barrier.\n* Pregnant, parturient, or breastfeeding patient.","ALL","18 Years",{"count":19,"type":20},77,"ESTIMATED","OBSERVATIONAL","Routine revascularization of asymptomatic carotid stenosis is questionable as optimal medical therapy has significantly reduced the risk of stroke. Therefore, it is crucial to identify high-risk patients who may still benefit from carotid revascularization. In 2017, the ESC guidelines clarified the criteria associated with a high risk of stroke despite optimal treatment to consider a revascularization procedure, including altered cerebral vasoreactivity. However, cerebral vasoreactivity using transcranial Doppler ultrasound is reserved for qualified centers. It requires a technical platform and trained personnel, is time-consuming and generally not readily available.\n\nA simpler test is therefore necessary. The goal is to quickly and easily detect patients with normal vasoreactivity who do not benefit from the cerebral vasoreactivity test (reference standard) and to reserve the time-consuming cerebral vasoreactivity test for patients likely to have altered vasoreactivity.\n\nThe hypothesis of the study is that on a routine measure in transcranial echo-Doppler, the resistance index (RI), can predict the response to the cerebral vasoreactivity test. With this new test, it will be possible to select patients who do not benefit from pharmacological cerebral vasoreactivity testing (\"true negatives\"). Thus, the time-consuming cerebral vasoreactivity test will be reserved only for patients with a possibility of impaired vasoreactivity.",[24,25],"Stenosis","Occlusion",[27],"Acetazolamide","RECRUITING","2026-05-28",{"date":31,"type":32},"2026-06-01","ACTUAL",{"date":34,"type":32},"2023-06-09",{"date":36,"type":20},"2029-06",{"name":38,"class":39},"Centre Hospitalier Universitaire de Nīmes","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":40},"100492429","phase-1-coffee-and-metabolites-modulating-the-gut-microbiome-in-colorectal-cancer-100492429","NCT05692024","COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER","COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER","COMMENCER","Inclusion Criteria:\n\nParticipants must meet the following criteria on screening examination to be eligible to participate in the study:\n\n* Participants must have histologically confirmed stage I, II, or III colon or rectal adenocarcinoma and have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago.\n* Age 18 years or older.\n* This study will only include adult participants because colorectal carcinogenesis in children is more likely to be related to a cancer predisposition syndrome with distinct biological mechanisms compared with sporadic colorectal cancer in adults.\n* The effects of coffee on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Subjects must be able and willing to follow study procedures and instructions.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nParticipants who exhibit any of the following conditions at screening will not be eligible for admission into the study.\n\n* Participants who are receiving any other investigational agents.\n* Concurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocol.\n* Regularly consuming more than 2 cups of coffee ( 8 oz) per day for at least 3 days a week in the past month.\n* Current or recent use (within 1 month) of any coffee supplements (e.g., green coffee extracts).\n* History of diagnosed conditions that may be worsen by coffee, including arrhythmias, insomnia, tremors, tics, generalized anxiety disorder, bipolar disease, panic attacks, Tourette's, epilepsy or overactive bladder.\n* History of adverse reactions to coffee or intolerance of coffee consumption.\n* Inability or unwillingness to swallow capsules.\n* History of malabsorption or uncontrolled vomiting or diarrhea, or any other disease that could interfere with absorption of oral medications.\n* Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness\u002Fsocial situations that, in the opinion of the investigator, may increase the risks associated with study participation or study treatment, limit compliance with study requirements, or interfere with the interpretation of study results.\n* Pregnant or breastfeeding. The effects of coffee on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.\n\nShould a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Similarly, lactating women are excluded from this study because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with coffee. Consequently, breastfeeding should be discontinued if the mother is enrolled on the study.\n\n* Presence of synchronous (at the same time) malignancy for which the patient is currently receiving active treatment.\n* Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.",{"count":50,"type":20},80,"INTERVENTIONAL",[53,54],"PHASE1","PHASE2","This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.",[57,58,59,24,60,61,62],"Colorectal Cancer","Coffee","Gastrointestinal Microbiome","Fibrosis, Liver","Ultrasound Elastography","Proton Magnetic Resonance Spectroscopy",[64,65,66,58,67],"Liver fat","Gut microbiome","Colorectal cancer","Tumor biopsy","2026-04-29",{"date":70,"type":32},"2026-05-05",{"date":72,"type":32},"2024-03-21",{"date":74,"type":20},"2028-08-31",{"name":76,"class":39},"Massachusetts General Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":51,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100407377","the-efemoral-vascular-scaffold-system-evss-for-the-treatment-of-patients-with-symptomatic-peripheral-vascular-disease-from-stenosis-or-occlusion-of-the-femoropopliteal-artery-100407377","NCT04584632","The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery","A Clinical Evaluation of the Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery","Efemoral I","Inclusion Criteria:\n\n* Symptomatic peripheral vascular occlusive disease (Rutherford-Becker Clinical Category 2-4)\n* Patient with life expectancy \\>36 months\n* Females of childbearing potential must have negative pregnancy test\n* Patient is able to provide informed consent\n* Patient agrees to undergo all protocol-required follow-up examinations and requirements at the investigational site.\n* Patient must be able to take antiplatelet and\u002For anticoagulant agents as prescribed\n* Single de novo native disease segment of the superficial femoral artery (SFA) or P1 popliteal segment\n* Reference vessel diameter ≥5.5 mm and ≤6.5 mm\n* Target lesion length ≤90 mm\n* Target lesion with ≥50% DS\n* Inflow artery and popliteal artery free from flow-limiting lesion (DS \\\u003C50%)\n\nExclusion Criteria:\n\n* Hemoglobin \\\u003C9.0 g\u002FdL\n* WBC \\\u003C3,000 cells\u002Fmm3\n* Platelet count \\\u003C80,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3\n* Acute or chronic renal dysfunction with creatinine \\>2.5 mg\u002Fdl (176 µmol\u002FL)\n* Severe liver impairment as defined by total bilirubin ≥3 mg\u002Fdl or two times increase over the normal level of SGOT or SGPT\n* A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticagrelor or sirolimus, or with contrast sensitivity for which the patient cannot be adequately pre-medicated\n* Patient requires a planned procedure that would necessitate discontinuation of antiplatelet therapy\n* Patient is unable to walk\n* Patient has undergone a percutaneous vascular intervention \\\u003C30 days prior to the planned index procedure\n* Patient is maintained on chronic hemodialysis\n* Patient has uncontrolled diabetes mellitus (HbA1c ≥7.0%).\n* Patient has had a myocardial infarction within the previous 30 days of the planned index procedure\n* Patient has had a stroke within the previous 30 days of the planned index procedure and\u002For has deficits from a prior stroke that limits the patient's ability to walk\n* Patient has unstable angina defined as rest angina with ECG changes\n* Patient has a local groin or acute systemic infection that has not been treated successfully or is currently under treatment\n* Patient has acute thrombophlebitis, deep vein thrombosis or chronic venous insufficiency in either extremity\n* Patient has other medical illnesses (e.g., cancer, congestive cardiomyopathy, etc.) that may cause the patient to be non-compliant with protocol requirements, confound the data interpretation or will prevent completion of all required follow up assessments through 36 months\n* Patient is currently participating in an investigational drug, biologic, or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints\n* Patient has ischemic or neuropathic ulcers on either foot\n* Patient has undergone minor or major amputation of either lower extremity\n* Patient is part of a vulnerable population who, in the judgment of the Investigator, is unable to give informed consent\n* Target extremity with an angiographically significant (\\>50% DS) lesion located distal to the target lesion that requires treatment at the time of the index procedure or by a staged procedure\n* Acute arterial ischemia of the target extremity\n* Target extremity has been previously treated with open surgical revascularization (bypass or endarterectomy)\n* Target vessel has been previously treated with stent, laser, atherectomy, surgical bypass, or endarterectomy\n* Total occlusion (100% DS) of the ipsilateral inflow artery\n* Angiographic evidence of thrombus in the target vessel\n* The target lesion requires treatment with a device other than percutaneous transluminal balloon angioplasty (PTA) \\[e.g., orbital atherectomy, directional atherectomy, excimer laser, rotational atherectomy, cryoplasty, etc.\\]\n* Target lesion is within or adjacent to an aneurysm\n* Patient has angiographic evidence of thromboembolism or atheroembolism from treatment of an ipsilateral iliac lesion or from crossing or pre-dilating the target lesion\n* Target lesion has moderate-to-severe calcification\n* Target lesion with \\> 30% residual stenosis following pre-dilatation",{"count":86,"type":20},100,[88],"NA","To evaluate the safety and performance of the EVSS in patients with symptomatic peripheral vascular disease from stenosis or occlusion of the femoropopliteal artery",[91,92,24,93],"Peripheral Arterial Disease","Vascular Diseases","Femoropopliteal Stenosis",[95,96],"Peripheral Artery Disease","Bioresorbable","2026-03-23",{"date":99,"type":32},"2026-03-25",{"date":101,"type":32},"2020-09-22",{"date":103,"type":20},"2030-03",{"name":105,"class":106},"Efemoral Medical, Inc.","INDUSTRY",8,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":21,"phases":4,"briefSummary":119,"conditions":120,"keywords":129,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":5},"100629458","targeting-real-world-usage-in-stroke-treatment-100629458","NCT07474935","Targeting Real World Usage In Stroke Treatment","TRUST Registry - Targeting Real World Usage In Stroke Treatment A WallabyPhenox Hemorrhagic Stroke Registry","TRUST","Inclusion Criteria:\n\n* Subject treated or intended to be treated with at least one target registry device during the procedure (i.e., at least one attempt of introduction into the vasculature of the subject),\n* Non-opposition to data collection or informed consent provided by the subject or legal representative as per country-specific legislation.\n\nExclusion Criteria:\n\n* Participation in an interventional study modifying standard care management for all relevant indications,",{"count":117,"type":20},5000,"5 Years","TRUST Registry is an observational, prospective, long-term, post-market surveillance registry of subjects treated with WallabyPhenox flow modulation devices, stent systems, bifurcation aneurysm implants including their HPC variants (Hydrophilic Polymer Coating) where applicable as well as coil systems, and other adjunctive medical devices.\n\nThe overarching purpose of this registry is to carry out a proactive gathering, recording, and analysis of data on the safety, performance and usability of the devices as applied within the routine practice of the participating registry sites.",[121,122,123,124,125,24,126,127,128],"Saccular and Fusiform Aneurysms","Pseudoaneurysm","Vascular Dissection","Perforation","Bifurcation Aneurysms","Neurovascular Abnormalties","Wide-neck Aneurysm","Intracranial Aneurysms",[130,131,132,133,134,135,136,137,138,139],"TRUST Registry","Registry study","Flow Diverter","WallabyPhenox","p48 MW (HPC)","p64","Avenir Coil","p64 MW (HPC)","pEGASUS HPC","pCONUS 2 (HPC)","2026-03-11",{"date":142,"type":32},"2026-03-16",{"date":144,"type":32},"2026-01-29",{"date":146,"type":20},"2041-01",{"name":148,"class":106},"Phenox GmbH",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":40},"100591940","beacon-tip-sizing-catheter-and-slip-cath-beacon-tip-catheter-study-100591940","NCT06986954","Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study","Inclusion Criteria:\n\n* A patient is deemed suitable for inclusion in this study if the patient undergoes a procedure using an applicable Beacon Tip Catheter.\n\nExclusion Criteria:\n\n* Patient or his\u002Fher legally authorized representative objects to collection and processing of his\u002Fher data, or not willing to accept the use of an Informed Consent waiver or the data protection notice (if utilized).",{"count":156,"type":20},588,"This prospective observational post-market clinical study will collect data in the United States to primarily support the re-launch of the re-designed Beacon Tip Sizing Catheter and Slip-Catheter Beacon Tip Catheter \\& Shuttle Select Slip-Catheter (Visceral and Cerbral) for a Conformité Européenne (CE) Mark application in the European Union (EU). Additionally, the data from this study may be used to support regulatory approval in other countries\u002Fregions.\n\nThe purpose of this clinical study is to evaluate the safety and performance of these catheters in accordance with the Intended Use through the end of index procedure, and through 30 days post procedure, (as applicable as data is available) to ensure an acceptable benefit:risk ratio.",[24,159,160,161,162,122],"Bleed Intracranial","Stroke","TIA","Vascular Malformation",[164,165,166,167,168],"Catheter","Beacon","Diagnostic imaging","Device sizing","Beacon tip slip cath","2025-07-15",{"date":171,"type":32},"2025-07-16",{"date":173,"type":32},"2025-04-20",{"date":175,"type":20},"2026-07-31",{"name":177,"class":106},"Cook Research Incorporated",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":40},"100598601","transcatheter-fontan-stenting-impact-on-hepatic-stiffness-and-exercise-capacity-100598601","NCT07073612","Transcatheter Fontan Stenting: Impact on Hepatic Stiffness and Exercise Capacity","Inclusion Criteria:\n\n* Functionally single-ventricle Fontan-palliated patients undergoing clinically indicated cardiac catheterization\n* Anticipated Fontan stent placement for extracardiac Fontan conduit stenosis at the discretion of the primary operator\n* Weight ≥ 50 kg\n* 12-21 years of age\n\nExclusion Criteria:\n\n* Interrupted IVC\n* Greater than mild atrioventricular valve regurgitation on most recent echocardiogram or MRI (RF \\> 20%).\n* Greater than mild systemic ventricular dysfunction on most recent echo or MRI (EF \\\u003C 40%).\n* Non-sinus rhythm\n* Pacemaker\n* Inability to perform exercise test due to developmental or physical disability","12 Years","21 Years",{"count":187,"type":20},20,"The goal of this observational study is to assess the clinical impact following Fontan stent placement for extracardiac Fontan conduit (EFC) stenosis in patients with single-ventricle Fontan-palliated patients ages 12-21 years old.\n\nThe main question it aims to:\n\n-Assess changes in exercise capacity by cardiopulmonary exercise testing and liver stiffness assessed by shear wave elastography before and after EFC stenting.\n\nParticipants will undergo two cardiopulmonary exercise tests and three shear wave elastography scans.",[190,24],"Single-ventricle",[192,193,190],"Stent","fontan","2025-07-10",{"date":196,"type":32},"2025-07-18",{"date":198,"type":20},"2025-08-01",{"date":200,"type":20},"2027-12-01",{"name":202,"class":39},"Children's Hospital Los Angeles",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":51,"phases":214,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":40},"100510107","oriental-intervention-for-enhanced-neurocognitive-health-orient-diet-in-patients-with-intracranial--carotid-stenosis-100510107","NCT05922137","Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) Diet in Patients With Intracranial \u002F Carotid Stenosis","Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) Diet in Patients With Intracranial \u002F Carotid Stenosis : a Randomized Controlled Trial","ORIENT","Inclusion Criteria:\n\n* Patients aged ≥ 40 years\n* ≥ 50% stenosis in unilateral intracranial \u002F carotid artery\n* Written informed consent available\n* Willingness to complete all assessments and participate in follow-up\n* Adequate Visual and auditory acuity to undergo neuropsychological testing\n\nExclusion Criteria:\n\n* Previous history of major head trauma and any intracranial surgery\n* Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions\n* Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement\n* Severe loss of vision, hearing, or communicative ability\n* Nuts, berries, olive oil, or fish allergies\n* Patients presenting a malignant disease with life expectancy \\\u003C 3 years\n* Participation in an ongoing investigational drug study\n\nExit Criteria:\n\n* Not meet the inclusion criteria\n* For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator\n* Any adverse or serious adverse events during the study period judged by Investigator","40 Years",{"count":213,"type":20},120,[88],"To test the effects of 6 month additional intervention of ORIENT diet versus usual medical treatment for Intracranial \u002F Carotid Stenosis on cognitive decline, multi-mode MRI image markers and serum and fecal biomarkers in a randomized controlled trial of 120 patients with intracranial \u002F carotid stenosis, who are aged older than 40 years and without dementia.",[217,218,24,219],"Cognitive Decline","Cognitive Change","Dementia",[221],"Cognitive decline","2025-06-11",{"date":224,"type":32},"2025-06-15",{"date":226,"type":32},"2023-05-01",{"date":228,"type":20},"2027-05-31",{"name":230,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":51,"phases":241,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":253,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":4},"100582868","six-month-response-rate-according-to-two-surgical-techniques-rotational-atherectomy-versus-angioplasty-to-treat-stenosis-of-vascular-accesses-in-hemodialysis-100582868","NCT06868901","Six-month Response Rate According to Two Surgical Techniques (Rotational Atherectomy Versus Angioplasty) to Treat Stenosis of Vascular Accesses in Hemodialysis.","Evaluation of the 6-month Response Rate According to Two Surgical Techniques (Rotational Atherectomy vs. Angioplasty) to Treat Stenosis of Vascular Accesses in Hemodialysis. A Single-center, Randomized, Single-blind, Superiority-controlled Pilot Study.","ARSAV","Inclusion Criteria:\n\n* Hemodialysis patient on arteriovenous fistula (AVF) with re-stenosis defined on echodoppler by a combination of \\>50% venous lumen reduction with a systolic peak ratio \\>2 associated with either : i) an internal residual diameter of \\\u003C 2 mm, or ii) a flow reduction \\> 25% or a flow rate \\\u003C 500 ml\u002Fmin.\n* Patient with at least one history of angioplasty on his\u002Fher AVF at the same site.\n* Patient available for 6-month follow-up.\n* Patient with free and informed consent and signed consent form.\n* Patient affiliated with or benefiting from a health insurance plan.\n\nExclusion Criteria:\n\n* Patient with an intraoperative technical impossibility.\n* Patient with a septic complication.\n* Patient participating in another interventional trial.\n* Patient in an exclusion period determined by another study.\n* Patient under court protection, guardianship or curatorship.\n* Patient unable to give consent.\n* Patient for whom it is impossible to give informed information.",{"count":240,"type":20},40,[88],"A well-functioning hemodialysis vascular access is a decisive factor in the survival of hemodialysis patients, who have a high mortality rate. 85% of these hemodialysis patients, are treated via an arteriovenous fistula (AVF). However, the primary patency of AVFs at 1 year is 60%, mainly due to neointimal hyperplasia developing in the drainage vein, which leads to stenosis and, if left untreated, thrombosis of the AVF. Indeed, forty percent of hemodialysis patients require re-intervention on their vascular access within the year, due to stenosis on their AVF.\n\nTransluminal angioplasty (TLA) is currently used as first-line treatment for these stenoses but TLA itself causes vascular damage, with early recurrence of the stenosis in 50% of cases at 6 months, and necessitating repeated interventions.\n\nIn recent years several endovascular techniques have been developed to limit the risk of re-stenosis, none of which have produced significantly better results than simple TLA. Eliminating intimal hyperplasia using a minimally invasive endovascular technique, rather than crushing it with simple angioplasty, would improve restenosis-free survival in these patients.\n\nToday, endovascular rotational atherectomy techniques are available to improve the patency of angioplasty in the treatment of complex arterial lesions of the coronary arteries and lower limbs. The atherotome is a guide-mounted catheter with a small burr at its distal end, which resects the atheromatous plaque whereas angioplasty simply crushes it. Atherectomy is followed by drug-eluting balloon (DEB) angioplasty with paclitaxel release to limit restenosis through its anti-inflammatory and anti-proliferative activity. A few cases of rotational atherectomy for the treatment of calcified stenoses in saphenous vein coronary bypasses have been reported in the literature, with encouraging results. If AVF re-stenosis should occur, the intimal hyperplasia can be removed endovascularly, thereby limiting the risk of short-term iterative stenosis.\n\nThe aim of this study was to compare the 6-month re-stenosis rate with this technique (atherectomy + drug-eluting balloon) versus standard angioplasty + drug-eluting balloon for the treatment of restenosis of hemodialysis vascular accesses.",[244,245,24],"Hemodialysis Complication","Dialysis Access Malfunction",[247,248,249,250,251,252],"Arteriovascular fistula","Angioplasty","Balloon","Atherectomy","Fistula","Re-stenosis","NOT_YET_RECRUITING","2025-03-05",{"date":256,"type":32},"2025-03-11",{"date":258,"type":20},"2025-03-01",{"date":200,"type":20},{"name":38,"class":39},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":268,"maxAge":269,"enrollmentInfo":270,"targetDuration":272,"studyType":21,"phases":4,"briefSummary":273,"conditions":274,"keywords":278,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":40},"100550415","pipeline-embolization-for-intracranial-aneurysms-100550415","NCT06446778","Pipeline Embolization for Intracranial Aneurysms","Pipeline Embolization Device for Intracranial Aneurysm (PEDIA): a Prospective, Multicenter Cohort Focus on Safety, Efficacy, and Haemodynamics","Inclusion criteria:\n\n1. Aged 22 to 75 years old, male or non-pregnant female;\n2. UIA was diagnosed by CTA, MRA, or DSA;\n3. The size of aneurysms is between 3 to 25mm;\n4. Understands the nature of the procedure and provision of written informed consent;\n5. Indications for FD implantation with or without adjunctive coiling;\n6. Is willing to return to the investigational site for follow-up according to our protocol.\n\nExclusion criteria:\n\n1. With contraindications to flow-diversion treatment or known allergy to cobalt-chromium alloy or contrast medium;\n2. Pregnancy or lactation;\n3. Coexist with other vascular lesions (coronary artery disease, abdominal aortic aneurysm, severe intracranial artery stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.);\n4. Parent vessel with a diameter \\\u003C2.0 mm or ≥5.0 mm.;\n5. Unwilling to be followed up or likely to have poor treatment compliance;\n6. Life expectancy less than 3 years;\n7. Inability to receive anti-platelet or anticoagulant medication;\n8. Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4);\n9. Enrollment in another trial or other situations that the researcher deems unsuitable for inclusion in the study.","22 Years","75 Years",{"count":271,"type":20},1000,"3 Years","This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization.",[275,276,24,277],"Efficacy, Self","Hemodynamic Instability","Aneurysm, Intracranial",[279,280,281,282],"intracranial aneurysms","flow-diverter device","Pipeline embolization device","in-stent stenosis","2024-11-13",{"date":285,"type":32},"2024-11-18",{"date":287,"type":32},"2022-09-01",{"date":289,"type":20},"2030-09-01",{"name":291,"class":39},"Zhujiang Hospital",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":299,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":51,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":253,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100559626","does-the-degree-of-cervical-stenosis-affect-proprioception-100559626","NCT06566573","Does the Degree of Cervical Stenosis Affect Proprioception?","Does the Degree of Stenosis Affect Cervical Proprioception in Patients With Cervical Problems?","Inclusion Criteria:\n\n* Individuals aged 18 and over\n* Previously performed cervical MRI\n* Cases whose stenosis classification can be clearly determined on MRI\n\nExclusion Criteria:\n\n* Individuals who did not agree to participate in the study\n* Individuals undergoing cervical surgery\n* Those with pain that restricts cervical movement\n* Those diagnosed with vertigo\n* Those with sudden hearing loss\n* Having additional neurological disorders\n* Those with psychiatric and cognitive disorders that would prevent measurement in the study",true,{"count":301,"type":20},108,[88],"Neck pain is a common health problem that negatively affects the quality of life of individuals of different age groups and most people experience this problem at some point in their lives. With age, changes occur in the neuromuscular functions of the cervical region that are considered normal. These changes lead to many problems such as postural disorder, decreased stabilization, loss of normal joint motion, balance disorders and decreased cervical joint position sense. When the literature was examined, the situation was observed that cervical proprioception, which is defined as joint position sense, has not been sufficiently investigated. In particular, researchers have not found any literature on how proprioceptive sensation varies according to the degree of cervical stenosis. Therefore, this study will provide a direction for the treatment of cervical region problems. The data will be discussed with appropriate statistical methods and treatment recommendations will be presented according to the results obtained.",[305,24],"Proprioceptive Disorders","2024-08-20",{"date":308,"type":32},"2024-08-22",{"date":310,"type":20},"2024-09-15",{"date":312,"type":20},"2025-09-15",{"name":314,"class":39},"Izmir Democracy University",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":40},"100535741","diagnosis-of-myocardial-ischemia-with-mcg-using-spect-as-a-reference-standard-100535741","NCT06255769","Diagnosis of Myocardial Ischemia With MCG Using SPECT as a Reference Standard","Identification of Myocardial Ischemia With Magnetocardiography Using Single Photon Emission Computed Tomography (SPECT) as a Reference Standard","Inclusion Criteria:\n\n* Age 18 years or older;\n* Patients with symptoms of myocardial ischemia such as angina pectoris, who have CAG showing \\\u003C70% stenosis at the most severe site or CTA showing non-severe stenosis\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with absolute or relative contraindications to SPECT-loaded myocardial perfusion, including acute myocardial infarction within 48 hours, significant left main coronary artery stenosis, bronchial asthma, and adenosine injection allergy;\n* Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy, or moderate or severe valvular disease;\n* Patients with Hemodynamic instability (systolic blood pressure\\\u003C90 mmHg, or who requires vasoactive drugs), or patients with tachyarrhythmia, Ⅱdegree atrioventricular block and above that have not returned to normal;\n* Patients who have severe renal abnormality with eGFR \\\u003C30 ml\u002Fmin, or patients who are on dialysis;\n* Patients with malignant tumors with predicted survival of less than 1 year;\n* Pregnant or breastfeeding women;\n* Patients who are unable to enter the MCG device, who are unable to perform MCG examination due to interference from metal implants or other reasons, or who are deemed by the investigators to be unsuitable for enrollment.",{"count":323,"type":20},228,"This is a prospective clinical study aiming to investigate the efficacy of Magnetocardiography (MCG) in detecting myocardial ischemia in patients of a suspected non-ST-elevation-acute coronary syndrome (NSTE-ACS) by using Single photon emission computed tomography (SPECT) as the gold standard for determining the presence and severity of myocardial ischemia.",[326,24,327],"Chest Pain","Myocardial Ischemia","2024-08-19",{"date":330,"type":32},"2024-08-21",{"date":332,"type":32},"2024-02-12",{"date":334,"type":20},"2024-12-31",{"name":336,"class":39},"Qilu Hospital of Shandong University",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":51,"phases":348,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":363},"100557559","a-trail-of-sperstent-used-for-residual-lesions-of-femoropopliteal-arteries-100557559","NCT06539689","A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries","A Prospective, Multicenter and Randomized Controlled Trial to Evaluate the Efficacy and Safety of Sperstent® Peripheral Spot Stent System Used for the Residual Lesions After Percutaneous Transluminal Angioplasty of Femoropopliteal Arteries","SURF","Inclusion Criteria:\n\n* Age 18-85 years old, male or female;\n* The target lesion is located in the superficial femoral artery or the proximal popliteal artery;\n* Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5;\n* Estimated life expectancy \\>1 year;\n* Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study.\n\nAngiographic Inclusion Criteria:\n\n* Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate);\n* Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions);\n* After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and\u002For presence of at least one post-PTA dissection (Type A-F) (by visual estimate);\n* Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%;\n* Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention).\n\nExclusion Criteria:\n\n* Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis;\n* Patients with serum creatinine \\>2.5mg\u002Fdl during screening or undergoing long-term hemodialysis or peritoneal dialysis;\n* Severe coagulation disorder;\n* Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery);\n* A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding);\n* Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment;\n* Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus;\n* Systemic infection or uncontrolled infection within the target limb;\n* Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics;\n* Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year;\n* Patients who are planning to have major lower limb amputations on the target side of the lesion;\n* Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery;\n* Participating in clinical trials of other medical devices or drugs;\n* The investigator considers the patient is not suitable for participation in the clinical trial.\n\nAngiographic Exclusion Criteria:\n\n* Failure of the guidewire to pass through the lesion；\n* During the procedure, the target lesions had received or were scheduled to receive volume reduction procedures such as cryogenic angioplasty, laser angioplasty, and percutaneous intracavity plaque gyrotomy；\n* The target lesion before stent implantation is thrombotic obliteration, which is not suitable for stent implantation；\n* The target lesions were severely calcified and could not fully predilate; Or grade 4 calcification；\n* Acute vascular occlusion or acute or subacute thrombosis in the target lesion；\n* Stent was implanted into the target vessel before enrollment.","85 Years",{"count":347,"type":20},240,[88],"This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular treatment of post-balloon angioplasty (post-PTA) residual lesions including stenoses and\u002For dissections in femoral and proximal popliteal arteries.",[91,24,351],"Dissection",[91,353],"Spot stent","2024-08-01",{"date":356,"type":32},"2024-08-06",{"date":358,"type":32},"2024-06-04",{"date":360,"type":20},"2026-12-31",{"name":362,"class":106},"FrontAce Scientific Co., Ltd",12,{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":372,"conditions":373,"keywords":375,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":40},"100464063","clinical-registration-study-of-patients-with-intracranial--carotid-stenosis-100464063","NCT05322824","Clinical Registration Study of Patients With Intracranial \u002F Carotid Stenosis","Inclusion Criteria:\n\n* Patients aged ≥ 40 years\n* ≥ 50% stenosis in unilateral intracranial \u002F carotid artery\n* Written informed consent available\n\nExclusion Criteria:\n\n* Previous history of major head trauma and any intracranial surgery\n* Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions\n* Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement\n* Severe loss of vision, hearing, or communicative ability\n\nExit Criteria:\n\n* Not meet the inclusion criteria\n* For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator\n* Any adverse or serious adverse events during the study period judged by investigator",{"count":371,"type":20},500,"Through prospective registration and follow-up, this study will collect data of patients with intracranial\u002Fcarotid stenosis, including clinical information, neuropsychological scales, multimodal magnetic resonance images. The investigators aim to analyze clinical and imaging characteristics of patients with cognitive impairment related to intracranial\u002Fcarotid stenosis, in order to achieve early identification of cognitive impairment.",[374,24],"Cognitive Function",[374,376],"Intracranial \u002F Carotid Stenosis","2023-04-16",{"date":379,"type":32},"2023-04-18",{"date":381,"type":32},"2022-01-01",{"date":383,"type":20},"2029-12-31",{"name":230,"class":39}]